Introduction {#Sec1}
============

Chemotherapy-induced nausea and vomiting (CINV) causes distress in cancer patients and reduces their quality of life \[[@CR1], [@CR2]\]. The prophylaxis of CINV has greatly improved since the appearance of the 5-hydroxytryptamine 3 (5-HT~3~) receptor antagonists (RAs) \[[@CR3], [@CR4]\] and the neurokinin 1 (NK~1~) RA aprepitant \[[@CR4]--[@CR6]\]. However, the prophylaxis of CINV is often suboptimal \[[@CR7]\]. If appropriate antiemetic therapy is not provided, 70--80 % of patients receiving emetogenic chemotherapy will experience CINV \[[@CR8]\]. Thus, the effective prophylaxis of CINV is a key aspect of patient care.

The current recommended standard of care (SoC) for CINV in patients receiving highly emetogenic chemotherapy (HEC) is dexamethasone plus aprepitant and a 5-HT~3~ RA. For moderately emetogenic chemotherapy (MEC), the recommended SoC is dexamethasone and a 5-HT~3~ RA with or without aprepitant, as recommended by a number of guidelines \[[@CR9]--[@CR13]\]. Although these guidelines are widely available, their use in clinical practice remains suboptimal \[[@CR14]\]. In addition, first-generation 5-HT~3~ RAs, such as ondansetron and granisetron (GRA), are less effective for the treatment of CINV in the delayed phase than in the acute phase \[[@CR4], [@CR15], [@CR16]\]. There is therefore an unmet need for more effective therapies to control CINV, which has led to the development of new-generation 5-HT~3~ RAs such as palonosetron (PALO).

PALO has a longer half-life, more potent binding, and unique molecular interactions with the 5-HT~3~ receptor in comparison with the first-generation 5-HT~3~ RAs \[[@CR4]\]. PALO allosterically binds to the 5-HT~3~ receptors with positive cooperativity, which most likely triggers the internalization of these receptors, leading to persistent inhibition of their function \[[@CR4]\]. In addition, PALO is able to inhibit 5-HT~3~/NK~1~ receptor signaling cross-talk, mediating the prophylaxis of delayed CINV in contradistinction to first-generation 5-HT~3~ RAs \[[@CR4]\]. It has shown efficacy in the prophylaxis of CINV in the acute and delayed phases as well as overall in a number of clinical studies \[[@CR17]\]. PALO has also been shown to be more effective than dolasetron \[[@CR18]\] and ondansetron \[[@CR19]\] in patients receiving MEC and more effective than ondansetron \[[@CR20]\] in patients receiving HEC. Additionally, a recent retrospective study in almost 10,000 patients with breast or lung cancer treated with carboplatin or cisplatin showed that patients initiated and maintained on PALO had a significantly lower risk of CINV than patients receiving first-generation 5-HT~3~ RAs \[[@CR21]\]. In a comparative phase 3 study of single-dose PALO and GRA, both administered with dexamethasone, involving 1114 Japanese patients receiving HEC, Saito et al. found that PALO was non-inferior to GRA for the control of CINV in the acute phase and superior to GRA in the delayed phase \[[@CR22]\].

When evaluating treatments to control CINV, risk factors for CINV should be taken into consideration. The efficacy of CINV prophylaxis can be influenced by the chemotherapeutic regimen and the patient's age, sex, and smoking history \[[@CR23], [@CR24]\]. Although a number of studies found that the efficacy of CINV prophylaxis was not affected by age \[[@CR25]--[@CR27]\], other studies reported contrasting results. Specifically, in women being treated for chemotherapy and receiving the 5-HT~3~ RA ondansetron combined with dexamethasone, acute CINV was better controlled in older patients (\>45 years) and in patients receiving non-cisplatin-containing chemotherapy \[[@CR28]\]. The 5-HT~3~ RA GRA has also been reported to be more effective in elderly patients \[[@CR29]\]. A recent study aiming to identify CINV risk factors showed that non-habitual alcohol intake and younger age (\<55 years) were risk factors for acute CINV and that female sex was a risk factor for both acute and delayed CINV \[[@CR24]\].

In trials evaluating CINV treatments, to assess the occurrence of nausea is also important. Nausea is reported to have a greater negative effect on daily life than vomiting \[[@CR1]\] and remains one of the most feared chemotherapy-related adverse events \[[@CR8]\]. The challenges of controlling chemotherapy-induced nausea are greater than those for chemotherapy-induced vomiting, mostly because nausea is less well understood at the neurochemical level \[[@CR30]\]. Therefore, many CINV treatments have been less successful for nausea control than for vomiting control \[[@CR31], [@CR32]\].

In a further analysis of the Japanese comparative phase 3 study conducted by Saito et al. \[[@CR22]\], the efficacy of PALO for the control of nausea was evaluated in the overall population and in subgroups stratified according to sex, type of chemotherapy (cisplatin or doxorubicin/epirubicin plus cyclophosphamide \[AC/EC\]), and age (\<55 or ≥55 years).

Patients and methods {#Sec2}
====================

Study design {#Sec3}
------------

Details of the study design have previously been published \[[@CR22]\] (ClinicalTrials.gov number: NCT00359567).

Nausea {#Sec4}
------

Evaluation of nausea was a secondary endpoint. The proportion of patients without nausea was assessed daily (days 1--5), during the acute phase (0--24 h), delayed phase (24--120 h), and overall (0--120 h). In addition, the proportion of patients without nausea was assessed according to the stratification factors including sex, age (\<55 or ≥55 years), and type of chemotherapy (cisplatin or AC/EC). Patient diaries were used to evaluate the degree of nausea in daily (24-h) intervals for 120 h after the start of chemotherapy. Nausea was defined as the feeling of being about to vomit. Nausea severity was categorized using a 4-point Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea, and 3 = severe nausea) according to the subjective assessment of each patient.

Statistics {#Sec5}
----------

The efficacy analyses were based on the modified intention-to-treat (ITT) cohort, which included all randomized patients who received the study drugs and HEC. The proportion of patients without nausea was assessed during the acute phase, the delayed phase, the overall study period, and at 24-h intervals throughout the 120 h. Baseline characteristics of the modified ITT cohort were summarized descriptively. Fisher's exact test was used to analyze the proportion of patients without nausea during the acute phase, delayed phase, and overall for the comparison of treatment arms. The Wilcoxon test was used to compare the severity of nausea in each 24-h period in all patients by arm.

The proportion of patients without nausea in each phase and throughout the 120 h at 24-h intervals was compared by the chi-square test between the treatment arms and between subgroups stratified by sex, age, and type of chemotherapy. All statistical tests were two-tailed. Statistical significance was set at *p* \< 0.05. SAS software version 8.2 (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analysis.

Results {#Sec6}
=======

Baseline characteristics {#Sec7}
------------------------

Of the 1143 patients randomized, 1119 patients were treated, 5 of whom were subsequently excluded from the efficacy analyses because of the insufficiently emetogenic chemotherapy. Thus, 1114 patients (*n* = 555 in the PALO arm; *n* = 559 in the GRA arm) were included in the modified ITT cohort for the efficacy analyses.

The baseline characteristics of the modified ITT cohort are shown in Table [1](#Tab1){ref-type="table"}. The sex distribution was comparable between the two treatment arms (58.7 % \[326/555 patients\] in the PALO arm vs. 58.0 % \[324/559\] in the GRA arm were female), as was the age distribution (67.7 % \[376/555\] vs. 68.0 % \[380/559\] ≥55 years, respectively). Prior to study initiation, the majority of patients in two arms (\>90 %) were chemotherapy naive. A similar proportion of patients in both study arms received cisplatin (56.9 % \[316/555\] vs. 57.8 % \[323/559\], respectively) or AC/EC (43.1 % \[239/555\] vs. 42.2 % \[236/559\], respectively).Table 1Baseline characteristics of the modified intention-to-treat cohortPalonosetron armGranisetron arm(*n* = 555)(*n* = 559)Gender, *n* (%) Female326 (58.7)324 (58.0) Male229 (41.3)235 (42.0)Age, years Mean (SD)58.4 (10.4)58.0 (10.5) ≥55 years, *n* (%)376 (67.7)380 (68.0) \<55 years, *n* (%)179 (32.3)179 (32.0)Tumor type, n (%) Non-small cell lung cancer248 (44.7)249 (44.5) Small cell lung cancer47 (8.5)52 (9.3) Breast cancer239 (43.1)236 (42.2) Others21 (3.8)22 (3.9)Chemotherapy, *n* (%) Cisplatin316 (56.9)323 (57.8) AC/EC239 (43.1)236 (42.2)Previous chemotherapy, *n* (%) Naive519 (93.5)516 (92.3) Non-naive36 (6.5)43 (7.7)*AC/EC* doxorubicin or epirubicin with cyclophosphamide, *SD* standard deviation

Nausea control {#Sec8}
--------------

On day 1, in the acute phase, the proportion of patients without nausea was similar in the PALO arm (58.7 % \[326/555\]) and in the GRA arm (59.9 % \[335/559\]). However, there was a significantly higher proportion of patients without nausea in the delayed phase (*p* = 0.0002) and overall (*p* = 0.0117) in the PALO arm than in the GRA arm (Fig. [1a](#Fig1){ref-type="fig"}). When assessed daily, the proportion of patients without nausea was significantly higher in the PALO arm than in the GRA arm on days 2, 3, 4, and 5 (all *p* \< 0.05) (Fig. [1b](#Fig1){ref-type="fig"}).Fig. 1Proportion of patients without nausea (**a**) in each phase and (**b**) on each day for each treatment arm. \**p* values determined by Fisher's exact test, \*\**p* \< 0.05 (chi-square test)

Severity of nausea over time was analyzed for both treatment arms (Fig. [2](#Fig2){ref-type="fig"}). The proportion of patients who experienced severe nausea was similar in two arms on day 1 (6.1 % \[34/555\] vs. 5.9 % \[33/559\]), but was lower in the PALO arm on day 2 (4.3 % \[24/553\] vs. 6.4 % \[36/559\]), day 3 (2.7 % \[15/552\] vs. 4.7 % \[26/559\]), day 4 (2.9 % \[16/552\] vs. 7.2 % \[40/559\]), and day 5 (1.6 % \[9/551\] vs. 5.0 % \[28/559\]). The severity of nausea was significantly lower in the PALO arm during the 24--48 h (*p* = 0.0180), 48--72 h (*p* = 0.0043), 72--96 h (*p* = 0.0005), and 96--120 h (*p* = 0.0030) periods than in the GRA arm.Fig. 2Severity of nausea over time for both treatment arms. \**p* \< 0.05 (Wilcoxon test). *PALO*, palonosetron; *GRA*, granisetron

The proportion of patients without nausea was also assessed according to the stratification factors including sex, age, and chemotherapy regimen. In male patients, no significant difference was noted between two arms in any phase. In the acute phase, the proportion of patients without nausea was slightly lower in the PALO arm than in the GRA arm (76.4 % \[175/229\] vs. 79.1 % \[186/235\]), whereas it was slightly higher in the delayed phase (40.6 % \[93/229\] vs. 35.3 % \[83/235\]) and overall (38.9 % \[89/229\] vs. 34.5 % \[81/235\]) (Fig. [3](#Fig3){ref-type="fig"}). In female patients, No significant difference was noted between the treatment arms in the acute phase (46.3 % \[151/326\] vs. 46.0 % \[149/324\]), but a significant difference was noted in the delayed phase (36.1 % \[117/324\] vs. 21.3 % \[69/324\]) and overall (27.0 % \[88/326\] vs. 18.2 % \[59/324\]), with a higher proportion of patients without nausea in the PALO arm than in the GRA arm (*p* \< 0.05) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Proportion of patients stratified by sex without nausea in each phase. \**p* \< 0.05 (chi-square test)

In the \<55 and ≥55 years age groups, the proportion of patients without nausea was similar between the two treatment arms in the acute phase (≥55 years, 69.1 % \[260/376\] vs. 68.4 % \[260/380\]; \<55 years, 36.9 % \[66/179\] vs. 41.9 % \[75/179\]) (Fig. [4](#Fig4){ref-type="fig"}). However, in both age groups, the proportion of patients without nausea was higher in the PALO arm than in the GRA arm in the delayed phase (≥55, 39.2 % \[147/375\] vs. 30.8 % \[117/380\]; \<55, 35.4 %, \[63/178\] vs. 19.6 % \[35/179\]) and overall (35.4 % \[133/376\] vs. 29.2 % \[111/380\]; \<55, 24.6 % \[44/179\] vs. 16.2 % \[29/179\]) (Fig. [4](#Fig4){ref-type="fig"}). The differences were significant in the delayed phase and overall in younger patients and in the delayed phase in older patients (all *p* \< 0.05).Fig. 4Proportion of patients stratified by age without nausea in each phase. \**p* \< 0.05 (chi-square test)

In the cisplatin and AC/EC chemotherapy groups, the proportion of patients without nausea was similar in the PALO and GRA arms in the acute phase (68.7 % \[217/316\] vs. 70.3 % \[227/323\] for cisplatin; 45.6 % \[109/239\] vs. 45.8 % \[108/236\] for AC/EC) (Fig. [5a](#Fig5){ref-type="fig"}). In the delayed phase and overall, the proportion of patients without nausea was higher in the PALO arm (37.0 % \[117/316\] and 34.8 % \[110/316\] for cisplatin; 39.2 % \[93/237\] and 28.0 % \[67/239\] for AC/EC) than in the GRA arm (27.9 % \[90/323\] and 27.2 % \[88/323\] for cisplatin; 26.3 % \[62/236\] and 22.0 % \[52/236\] for AC/EC) (Fig. [5a](#Fig5){ref-type="fig"}). The differences were significant in the delayed phase and overall in the cisplatin chemotherapy group and in the delayed phase in the AC/EC chemotherapy group (all *p* \< 0.05).Fig. 5Proportion of patients stratified by chemotherapy treatment without nausea **a** in each phase and **b** in each 24-h interval. \**p* \< 0.05 (chi-square test). Cisplatin or doxorubicin/epirubicin plus cyclophosphamide(AC/EC)

In patients stratified by chemotherapy, the proportion of patients without nausea was also analyzed daily (Fig. [5b](#Fig5){ref-type="fig"}). In the cisplatin-treated group, the proportion of patients without nausea was similar for both PALO and GRA arms on days 1, 2, and 3 (68.7 % \[217/316\], 55.1 % \[174/316\], 52.2 % \[165/316\] vs. 70.3 % \[227/323\], 52.3 % \[169/323\], 48.0 % \[155/323\]), but was significantly higher in the PALO arm on day 4 (49.1 % \[155/316\] vs. 39.6 % \[128/323\]; *p* \< 0.05) and day 5 (56.5 % \[178/315\] vs. 44.0 % \[142/323\]; *p* \< 0.05). In the AC/EC-treated group, the proportion of patients without nausea was similar with PALO and GRA treatments on day 1 (45.6 % \[109/239\] vs. 45.8 % \[108/236\]) and day 5 (69.1 % \[163/236\] vs. 69.5 % \[164/236\]), but was higher with PALO treatment on days 2, 3, and 4 (51.5 % \[122/237\], 51.7 % \[122/236\], 53.8 % \[127/236\] vs. 38.1 % \[90/236\], 41.1 % \[97/236\], 44.9 % \[106/236\]). This difference was significant on days 2 and 3 (both *p* \< 0.05) (Fig. [5b](#Fig5){ref-type="fig"}).

Discussion {#Sec9}
==========

In this post hoc analysis of Saito et al.'s phase 3 study in Japanese patients receiving HEC \[[@CR22]\], PALO achieved significantly better control of nausea than GRA in the overall study population during the delayed phase, overall, and during each day of the delayed phase. When evaluated by subgroups for age, sex, and type of chemotherapy, the proportion of "nausea-free" patients in the delayed phase was higher with PALO treatment than with GRA treatment, and the difference was significant in female patients, both age groups, and both chemotherapy groups. It is of particular interest that PALO protects against nausea in the delayed phase in female patients and in both age groups because a recent pooled analysis of two phase 2 trials and one phase 3 trial of PALO showed that younger age (\<55 years) is a risk factor for acute CINV and that female sex is a risk factor for both acute and delayed CINV \[[@CR24]\].

Treatment outcome and survival are reported to be associated with the relative dose intensity of chemotherapy \[[@CR33], [@CR34]\]. Therefore, when administering chemotherapy, it is also necessary to give appropriate supportive care treatment to achieve maximal benefit, with consideration of the related side effects. The most dreaded adverse effects of chemotherapy that have long been recognized are nausea and vomiting \[[@CR35]\]. In a recent multicenter, prospective, observational study in Japan, it was reported that nausea and vomiting during the acute phase were relatively well controlled but the incidence of nausea during the delayed phase was high in the patients receiving HEC and MEC. Such adverse events lead to loss of appetite, which is related to poor treatment outcomes and short survival \[[@CR36]\]. Also, this study reported that female sex and age were risk factors for acute and delayed nausea. Cancer patients tend to report symptoms, such as nausea and vomiting, earlier and more frequently than clinicians. In addition, patients' reports were found to have a higher concordance than clinicians' reports with overall health status \[[@CR37], [@CR38]\]. The incidence of CINV may also be considerably underestimated by healthcare providers, particularly in the delayed phase \[[@CR39]\]. The incidence of delayed CINV was underestimated by 75 % of physicians and nurses after the treatment of HEC and MEC. Delayed nausea in particular was underestimated by 21 percentage points after HEC and 28 percentage points after MEC \[[@CR37]\]. Delayed nausea and vomiting are still important targets in the development of improved antiemetics. Effective treatments are needed especially for nausea, as this adverse event reduces cancer patients' quality of life considerably \[[@CR1]\]. However, in spite of advanced understanding of the physiology of CINV, the ability to treat nausea remains poor as its neurochemistry seems much more complex \[[@CR30]\].

A recent trial reported that PALO was as effective as GRA in the prophylaxis of delayed nausea \[[@CR40]\]. However, comparison between their study and ours is complex due to differences in experimental setup and data reporting \[[@CR41]\]. The findings from our study are consistent with those from several phase 3 clinical trials showing that PALO has superior efficacy in nausea control in comparison with first-generation 5-HT~3~ RAs \[[@CR18]--[@CR20], [@CR42]\]. In the MEC setting, it has been reported that the proportion of patients who experience no nausea was significantly greater in those receiving PALO than in those receiving dolasetron on days 2 and 3 of treatment \[[@CR18]\]. Accordingly, another phase 3 study showed better control of nausea with PALO than with ondansetron on days 3, 4, and 5 of treatment \[[@CR19]\]. In the HEC setting, Aapro et al. also reported higher protection from acute nausea in patients treated with PALO than in those treated with ondansetron, although differences between the treatment arms did not reach statistical significance \[[@CR20]\].

A recent meta-analysis of 16 randomized controlled trials showed that, in general, PALO was statistically superior to first-generation 5-HT~3~ RAs in terms of complete response, complete control, without emesis, and without nausea. Particularly, in both the delayed phase and overall in the studies including corticosteroid, the proportion of patients who experience no nausea was significantly higher in those receiving PALO compared with those receiving first-generation 5-HT~3~ RAs \[[@CR43]\]. Taken together, the great majority of studies suggested better nausea control outcomes with PALO during the delayed phase than with first-generation 5-HT~3~ RAs. Furthermore, Aogi et al. reported that PALO plus dexamethasone was effective for the control of nausea in multiple cycles of HEC \[[@CR44]\].

In conclusion, in this study, PALO was found to be more effective than GRA in prophylaxis of nausea induced by HEC, both in the delayed phase and overall. Subgroup analysis showed that PALO was more effective than GRA in young patients and female patients, who are at high risk of CINV, both in the delayed phase and overall.
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